Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech companies publish some of the most technical disclosures on EDGAR, and Zevra Therapeutics is no exception. R&D expense swings tied to rare-disease trials, updates on FDA orphan-drug designations, and dilution from financing rounds all live inside 10-K, 10-Q, and 8-K forms that regularly top 200 pages. If you have ever typed “how do I read Zevra Therapeutics’ 10-K?” this page delivers Zevra Therapeutics SEC filings explained simply.
Stock Titan’s AI parses every line the moment it hits the tape, then surfaces what matters. Need the latest Zevra Therapeutics quarterly earnings report 10-Q filing? We highlight trial-spend by program and cash runway in plain English. Curious about Zevra Therapeutics insider trading Form 4 transactions before a data release? Get Zevra Therapeutics Form 4 insider transactions real-time alerts. Our platform also tags Zevra Therapeutics 8-K material events explained and turns them into concise summaries, so you can focus on decision-making instead of document hunting.
Drill deeper with our AI-powered tools:
- Zevra Therapeutics annual report 10-K simplified – see pipeline status, orphan-drug exclusivity timelines, and revenue assumptions in minutes.
- Zevra Therapeutics earnings report filing analysis – track quarter-over-quarter cash burn and partnership revenue.
- understanding Zevra Therapeutics SEC documents with AI – tap sectional notes that translate accounting jargon.
- Zevra Therapeutics executive stock transactions Form 4 – monitor how leadership reacts to pivotal trial milestones.
- Zevra Therapeutics proxy statement executive compensation – decode incentive structures tied to clinical success.
All filings update in real time, are searchable by keyword, and come with exportable data tables—because biotech diligence should be precise, not painful.
Zevra Therapeutics, Inc. (ZVRA) – Form 4 filing dated 06/24/2025
The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded “M,” indicating a conversion of a derivative security rather than an open-market purchase or sale.
Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.
No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
What is the core focus of Zevra Therapeutics Inc?
How does Zevra Therapeutics generate its revenue?
What differentiates Zevra’s development strategy in the rare disease space?
How is Zevra Therapeutics structured to address complex drug development challenges?
What role do strategic partnerships play in Zevra’s operations?
How does Zevra Therapeutics ensure its therapies address real patient needs?
